Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
Cash Flow PerformanceElevated
Percentile Rank25
Studio
Year-over-Year Change

Free cash flow yield

Latest
-81.23%
↑ 53% vs avg
Percentile
P25
Within normal range
Streak
1 yr
Consecutive growthElevated
Average
-173.19%
Historical baseline
PeriodValueYoY Change
2024-81.23%+93.3%
2023-1220.19%-2055.2%
2022-56.61%-41.3%
2021-40.07%-91.4%
2020-20.93%-232.5%
2019-6.30%-91.5%
2018-3.29%-115.5%
201721.21%+111.3%
2016-187.99%-37.7%
2015-136.56%-